William LaFramboise

Chief Genomics Technology Officer, Professor

Alleghgeny Health Network

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

William LaFramboise serves as the Chief Genomics Technology Officer and Professor at Allegheny Health Network in the United States. His research primarily focuses on the intersection of genomics and immunology in cancer treatment, particularly melanoma and gastrointestinal cancers. Recent publications highlight his work on tumor molecular concordance, immune signatures, and prognostic indicators in various malignancies. Dr. LaFramboise is committed to advancing the understanding and application of genomic technologies in personalized medicine.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Kunhong Xiao

Associate Professor

UNITED STATES

View details

Aik Choon Tan

University of Utah

UNITED STATES

View details

Lisa Butterfield

Adjunct Professor

University of California, San Francisco

UNITED STATES

View details

Walter Storkus

Professor

University of Pittsburgh

UNITED STATES

View details

Chad Storer

Washington University in St. Louis

UNITED STATES

View details

Ajay Goel

Professor and Chair, Dept. of Molecular Diagnostics and Experimental Therapeutics; Associate Director of Basic Sciences, City of Hope Comprehensive Cancer Center

Beckman Research Institute, City of Hope

UNITED STATES

View details

Lucas Santana-Santos

Assistant Professor

Northwestern University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William LaFramboise

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care Network

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Intra-Tumoral CD8+:CD3+ Lymphocyte Density Ratio in Appendix Cancer Is a Tumor Volume- and Grade-Independent Predictor of Survival

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.

Crohn's disease-associated ATG16L1 T300A genotype is associated with improved survival in gastric cancer

Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms

Multifocal Extraprostatic Extension of Prostate Cancer: A Third Subtype with Worse Prognosis Than Focal Prostate Cancer

Ultrasonic-assisted extraction and digestion of proteins from solid biopsies followed by peptide sequential extraction hyphenated to MALDI-based profiling holds the promise of distinguishing renal oncocytoma from chromophobe renal cell carcinoma

Collaborators (7)

Kunhong Xiao

Aik Choon Tan

Lisa Butterfield

Walter Storkus

Chad Storer

Ajay Goel

Lucas Santana-Santos

Make your next move.